Clene (CLNN) Competitors $5.66 +0.32 (+5.99%) Closing price 04:00 PM EasternExtended Trading$5.42 -0.24 (-4.22%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CLNN vs. TARA, IOBT, GNLX, AVTX, IMRX, CNTB, LIMN, CLYM, IKT, and SCLXShould you be buying Clene stock or one of its competitors? The main competitors of Clene include Protara Therapeutics (TARA), IO Biotech (IOBT), Genelux (GNLX), Avalo Therapeutics (AVTX), Immuneering (IMRX), Connect Biopharma (CNTB), Liminatus Pharma (LIMN), Climb Bio (CLYM), Inhibikase Therapeutics (IKT), and Scilex (SCLX). These companies are all part of the "pharmaceutical products" industry. Clene vs. Its Competitors Protara Therapeutics IO Biotech Genelux Avalo Therapeutics Immuneering Connect Biopharma Liminatus Pharma Climb Bio Inhibikase Therapeutics Scilex Clene (NASDAQ:CLNN) and Protara Therapeutics (NASDAQ:TARA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk. Do analysts recommend CLNN or TARA? Clene presently has a consensus target price of $33.00, indicating a potential upside of 483.04%. Protara Therapeutics has a consensus target price of $19.60, indicating a potential upside of 530.23%. Given Protara Therapeutics' higher possible upside, analysts clearly believe Protara Therapeutics is more favorable than Clene.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Clene 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17Protara Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 Do insiders and institutionals have more ownership in CLNN or TARA? 23.3% of Clene shares are owned by institutional investors. Comparatively, 38.1% of Protara Therapeutics shares are owned by institutional investors. 35.3% of Clene shares are owned by company insiders. Comparatively, 8.4% of Protara Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Is CLNN or TARA more profitable? Protara Therapeutics has a net margin of 0.00% compared to Clene's net margin of -10,386.36%. Clene's return on equity of 0.00% beat Protara Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Clene-10,386.36% N/A -125.49% Protara Therapeutics N/A -36.87%-33.85% Which has more volatility & risk, CLNN or TARA? Clene has a beta of 0.55, indicating that its share price is 45% less volatile than the S&P 500. Comparatively, Protara Therapeutics has a beta of 1.42, indicating that its share price is 42% more volatile than the S&P 500. Does the media favor CLNN or TARA? In the previous week, Clene had 3 more articles in the media than Protara Therapeutics. MarketBeat recorded 12 mentions for Clene and 9 mentions for Protara Therapeutics. Protara Therapeutics' average media sentiment score of 0.62 beat Clene's score of -0.24 indicating that Protara Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Clene 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Protara Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings and valuation, CLNN or TARA? Clene has higher revenue and earnings than Protara Therapeutics. Protara Therapeutics is trading at a lower price-to-earnings ratio than Clene, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioClene$340K166.30-$39.40M-$3.76-1.51Protara TherapeuticsN/AN/A-$44.60M-$1.62-1.92 SummaryProtara Therapeutics beats Clene on 7 of the 13 factors compared between the two stocks. Get Clene News Delivered to You Automatically Sign up to receive the latest news and ratings for CLNN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CLNN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLNN vs. The Competition Export to ExcelMetricCleneMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$53.35M$3.11B$5.76B$9.58BDividend YieldN/A2.23%4.41%4.09%P/E Ratio-1.5120.8831.1026.05Price / Sales166.30356.38436.12105.98Price / CashN/A43.1937.7358.48Price / Book-6.588.129.536.61Net Income-$39.40M-$54.72M$3.26B$265.56M7 Day Performance56.35%2.62%2.11%1.98%1 Month Performance48.56%7.63%5.12%1.33%1 Year Performance6.79%13.11%31.25%21.15% Clene Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLNNClene3.271 of 5 stars$5.66+6.0%$33.00+483.0%+3.5%$53.35M$340K-1.51100Analyst ForecastTARAProtara Therapeutics1.8397 of 5 stars$3.10-1.0%$20.50+561.3%+44.2%$120.76MN/A0.0030News CoverageAnalyst RevisionIOBTIO Biotech3.335 of 5 stars$1.05-42.0%$9.33+788.9%+12.0%$119.24MN/A0.0030High Trading VolumeGNLXGenelux1.529 of 5 stars$3.28+4.1%$17.75+441.2%+67.8%$118.99M$10K0.0010News CoverageAVTXAvalo Therapeutics3.2364 of 5 stars$9.01+0.9%$30.00+233.0%+8.3%$117.45M$440K0.0040News CoverageIMRXImmuneering3.6037 of 5 stars$3.21-1.2%$13.25+312.8%+313.4%$116.95M$320K0.0060News CoverageCNTBConnect Biopharma3.5409 of 5 stars$2.05-1.0%$7.00+241.5%+65.6%$115.01M$26.03M0.00110Positive NewsAnalyst UpgradeLIMNLiminatus PharmaN/A$4.48+1.4%N/AN/A$114.99MN/A0.00N/AGap UpCLYMClimb Bio3.5816 of 5 stars$1.65-2.9%$9.00+445.5%N/A$114.88MN/A0.009IKTInhibikase Therapeutics1.7514 of 5 stars$1.51+5.6%$6.50+330.5%+15.9%$112.26MN/A-0.576Gap UpSCLXScilex2.4964 of 5 stars$15.82+0.6%$455.00+2,776.1%-60.5%$109.28M$56.59M0.0080News Coverage Related Companies and Tools Related Companies TARA Competitors IOBT Competitors GNLX Competitors AVTX Competitors IMRX Competitors CNTB Competitors LIMN Competitors CLYM Competitors IKT Competitors SCLX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CLNN) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredUS attacks China, September 30?The White House just ordered more than 400 government agencies to prepare for the next phase of America’s econ...Stansberry Research | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clene Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Clene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access